Company intelligence / Profile preview

Cytometix

Milwaukee, Wisconsin, United Statespitchbook.com ↗

Ownership: Private
Development stage: Phase 2

Overview

As of the last available information, Cytometix had raised $1.9 million to advance a novel small molecule pain therapeutic toward an IND filing and potential Phase 1 trials. The company also had an asthma drug candidate in earlier development. No clinical results have been published or reported.

Therapeutic areas: PulmonologyNeurology
Modalities: Small molecules
Industry: Biotech

Drug pipeline

1 asset

CMX-020

Phase 2

Indications: Pain, Osteoarthritis, Diabetic neuropathy, Chemotherapy-induced neuropathy, Fibromyalgia, Sciatica

Partnerships

Collaboration with Medical College of Wisconsin for preclinical research and scientific consulting support

Beyond the preview

Go deeper on Cytometix.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cytometix.

Explore the full profile